For the quarter ending 2025-09-30, VSTM had -$26,616K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Revenue-Product | 13,379 | - |
| Cost of sales - product | 1,988 | - |
| Cost of sales - intangible amortization | 418 | - |
| Research and development expenses | 80,938 | - |
| Commercial expenses | 22,282 | - |
| Medical affairs expenses | 7,615 | - |
| General and administrative expenses | 21,414 | - |
| Stock-based compensation expense | 7,379 | - |
| Depreciation expense | 12 | - |
| Interest income | 2,964 | - |
| Interest expense | 723 | - |
| Loss on debt extinguishment | -1,826 | - |
| Change in fair value of warrant liability | 37,977 | - |
| Change in fair value of notes | 10,153 | - |
| Other segment items | 173 | - |
| Net loss | -98,518 | -78,037 |
| Depreciation | 2 | 10 |
| Amortization of acquired intangible asset | 290 | 128 |
| Non-cash operating lease cost | -18 | -44 |
| Stock-based compensation expense | 2,178 | 5,201 |
| Amortization of deferred financing costs, debt discounts and premiums and discounts on available-for-sale marketable securities | 0 | 29 |
| Change in fair value of warrant liability | 55,881 | -17,904 |
| Non-cash change in fair value of notes | 1,105 | 4,565 |
| Loss on debt extinguishment | -3,652 | 1,826 |
| Accrued expenses, long term | - | 6,264 |
| Accounts receivable, net | 4,640 | 2,076 |
| Inventory | 626 | 1,168 |
| Prepaid expenses, other current assets and other assets | 1,103 | 795 |
| Accounts payable | 497 | 4,021 |
| Accrued expenses and other liabilities | 15,000 | 6,641 |
| Net cash used in operating activities | -36,216 | -71,339 |
| Purchases of intangible asset | 8,279 | - |
| Net cash (used in) provided by investing activities | -8,279 | - |
| Proceeds from long-term debt | 0 | 75,000 |
| Repayment of long-term debt | 0 | 42,580 |
| Proceeds from insurance premium financing | 0 | 1,180 |
| Payments on insurance premium financing | 278 | 714 |
| Proceeds from the exercise of stock options and employee stock purchase program | 74 | 22 |
| Proceeds from exercise of warrants | 18,083 | 13,840 |
| Proceeds from the issuance of common stock and pre-funded warrants, net | 0 | 100,095 |
| Net cash provided by financing activities | 17,879 | 146,843 |
| Increase in cash, cash equivalents and restricted cash | -26,616 | 75,504 |
| Cash and cash equivalents at beginning of period | 89,059 | - |
| Cash and cash equivalents at end of period | 137,947 | - |
Verastem, Inc. (VSTM)
Verastem, Inc. (VSTM)